Advertisement

CXCR4 Imaging in Multiple Myeloma

  • M. I. Morales
  • C. Lapa
  • A. K. BuckEmail author
Chapter

Abstract

The C–X–C chemokine receptor 4 (CXCR4) and its natural ligand CXCL12 are key factors in the process of cell migration, homing of hematopoietic stem cells to the bone marrow, and represent important mediators of angiogenesis and cell proliferation. In many pathological conditions, such as multiple myeloma, high CXCR4 expression is frequently observed and associated with tumor dissemination as well as prognosis. This makes CXCR4 an attractive target for imaging and treatment of malignant diseases.

Recently, radiolabeled analogs of CXCR4 antagonists (e.g., [68Ga]Pentixafor) have been introduced for non-invasive imaging of CXCR4 expression in preclinical and humans models using positron emission tomography techniques. Furthermore, a therapeutic strategy is also possible with the addition of beta emitter-labeled antagonists (i.e., [177Lu]/[90Y]Pentixather), already used in small cohorts of multiple myeloma patients with promising results. This chapter reports on current imaging protocols for CXCR4-directed positron emission tomography in multiple myeloma patients. The theranostic approach will not be the subject of extensive revision in this chapter, devoted, almost entirely, to the evaluation of multiple myeloma by CXCR4-PET/CT.

Keywords

C-X-C chemokine receptors Microenvironment Positron emission tomography Theranostics Multiple myeloma 18F-FDG Bone marrow Extramedullary lesions 

References

  1. 1.
    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.CrossRefGoogle Scholar
  2. 2.
    Mitsiades CS, et al. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local environment. J Cell Biochem. 2007;101:950–68.CrossRefGoogle Scholar
  3. 3.
    Nagasawa T, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382(6592):635–8.CrossRefGoogle Scholar
  4. 4.
    Domanska UM, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–30.CrossRefGoogle Scholar
  5. 5.
    Alsayed Y, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708–17.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Vande Broek I, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica. 2006;91(2):200–6.PubMedGoogle Scholar
  7. 7.
    Spano JP, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15(4):613–7.CrossRefGoogle Scholar
  8. 8.
    Hermann K, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease. J Nucl Med. 2016;57(2):248–51.CrossRefGoogle Scholar
  9. 9.
    Lapa C, et al. Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. Br J Haematol. 2019;184(3):440–3.CrossRefGoogle Scholar
  10. 10.
    Lapa C, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma—comparison to [18F]FDG and laboratory values. Theranostics. 2017;7(1):205–12.CrossRefGoogle Scholar
  11. 11.
    Werner RA, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors—a triple tracer comparative approach. Theranostics. 2017;7(6):1489–98.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineClinica Universidad de NavarraPamplonaSpain
  2. 2.Department of Nuclear MedicineUniversity Hospital WürzburgWürzburgGermany

Personalised recommendations